A mitochondria-related gene-based signature predicts pancreatic ductal adenocarcinoma clinical outcome and revealed CAMK2A/THEM4 regulates progression phenotypes and mitophagy in vivo and in vitro

This study establishes a mitochondria-driven prognostic model for PDAC and identifies the CAMK2A-THEM4-AKT axis as a novel therapeutic target. To our knowledge, this is the first pancreatic cancer signature that investigates the synergistic effect of candidate genes, offering both prognostic and mechanistic insights into PDAC progression.